Latest news with #Associationfor
Business Wire
28-07-2025
- Business
- Business Wire
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories. It also features its rapid next-generation sequencing (NGS) technology, recently approved by the U.S. Food and Drug Administration (FDA), the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer, for use as a companion diagnostic for Dizal's ZEGFROVY® (sunvozertinib) and for tumor profiling applications. 'Our solutions harness our scientific expertise to enhance care by enabling earlier and more precise detection and diagnosis. In partnership with our customers, we're working every day to bring better, faster and safer diagnostics to all patients,' said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. 'At Thermo Fisher, we are committed to advancing diagnostics that address today's most pressing global health challenges by boosting efficiency and reducing overall laboratory costs — ultimately driving more optimal patient care.' Harnessing Innovation for Quality Assurance, Efficiency and Sustainability in the Clinical Lab Clinical laboratories rely on quality assurance programs (QAPs) to ensure test result accuracy, which is essential for proper diagnosis and treatment. In resource-limited settings, a QAP that delivers quick, actionable insights can ease operational bottlenecks, improve workflow efficiency and enhance data-driven decisions. Thermo Fisher's new LabLink360 is a next-generation QAP software designed to help enhance patient safety, reduce errors and elevate healthcare quality. It features Sigma-metric analysis, a global benchmarking tool that helps labs assess performance and optimize quality control parameters based on results. Thermo Fisher also recently launched the Thermo Scientific MAS Omni•CORE ™ Max load-and-go quality controls (QC) to help simplify and automate lab workflows, allowing lab technicians to be more efficient and focus more on delivering fast and accurate patient results. The Omni•CORE Max QCs are part of a portfolio of QCs for clinical diagnostic testing, including the MAS Diabetes Max, which can help labs reduce daily QC bottles by up to 54% and lot-to-lot validations by up to 77%.** Beyond supporting the improved efficiency of laboratories, Thermo Fisher is also committed to supporting customers' sustainability initiatives. While most labs print patient results, QC, calibrations and other instrument data and place them in storage, this practice contributes to a staggering environmental impact. The company will present a poster and a micro-lecture explaining the transformative benefits of transitioning to a paperless laboratory environment. Targeting Unmet Diagnostic Needs Approximately 85% of patients in the U.S. receive cancer care in community settings. However, these sites have historically lacked consistent access to rapid and reliable next-generation sequencing, which is playing a growing role in informing precision oncology treatment decisions. At ADLM, the company will present its rapid NGS solution, the Oncomine Dx Express Test on the Ion Torrent Genexus Integrated Sequencer. Available as both an RUO solution and for clinical use on the Genexus Dx System, more care teams can now access NGS results in as little as 24 hours*** to help make more informed treatment recommendations for their patients, while also sparing patients from unnecessary delays, procedures and uncertainty. Also helping expand vital testing the company will highlight its PreClara™ Ratio,**** cleared in 2023 and previously known as B·R·A·H·M·S™ sFlt-1/PlGF KRYPTOR™ Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing. As the first FDA-cleared biomarker test for preeclampsia risk assessment, the PreClara Ratio provides reliable, quantifiable results with excellent analytical and clinical performance. When combined with other laboratory tests and standard clinical assessment, the PreClara Ratio may enable more informed clinical decisions, with the aim of improving health outcomes for both mothers and their babies. Thermo Fisher will also highlight its EXENT ® Solution, a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The EXENT Solution enables more sensitive analytical methods that can differentiate between patient subsets without requiring invasive bone marrow biopsy techniques too early. It is currently available for clinical use in Brazil, Belgium, France, Germany, Italy, the Netherlands, New Zealand, Spain, the United Kingdom, Switzerland and Australia. Thermo Fisher is also presenting its latest solutions for allergy and autoimmune diagnostics, oncology, women's health and quality control testing. In the booth, attendees can engage with a series of dynamic micro-lectures designed to advance industry knowledge and clinical expertise. These sessions cover a wide range of diagnostic topics and innovations, offering valuable insights into improving testing efficiency, patient outcomes and disease detection strategies. For more information on Thermo Fisher's activities at ADLM, please visit or conference booth (2812) to experience the full breadth of Thermo Fisher's diagnostic solutions. * Not yet commercially available. ** Will vary for each laboratory depending on the configuration. Data on file. ***Timing varies by number of samples and type of run. ****Brand trademarked in the U.S. only. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Yomiuri Shimbun
13-07-2025
- Yomiuri Shimbun
3 Months After Expo's Opening, Visitors Top 10 Mil.; 164,000 Visitors Attend on Saturday
OSAKA — A total of 10.08 million general visitors have attended the 2025 Osaka-Kansai Expo in the three months since its opening on April 13 through Saturday, according to the Japan Association for the 2025 World Exposition. Also, preliminary visitor numbers for Saturday totaled 164,000, marking the third highest daily figure, the association said Sunday, one day after an aerobatic demonstration by the Blue Impulse, a team of Air Self-Defense Force pilots. With three months having passed since the Expo kicked off, the six-month-long event reached its halfway point on Sunday. The association projects 28.2 million people will have visited the Expo by the time it ends. However, the current pace is slower than what has been projected. Nevertheless, the association expects the numbers to pick up during the summer vacation period and toward the end of the Expo. The association also plans to strengthen its efforts to attract visitors from outside the Kansai region.
Hamilton Spectator
14-05-2025
- Politics
- Hamilton Spectator
The Association for Responsible Aquaculture Reports Allegations of Bid-Rigging in Nova Scotia Aquaculture Expansion
ARGYLE, Nova Scotia, May 13, 2025 (GLOBE NEWSWIRE) — The Association for Responsible Aquaculture (ARA) reports that the coastal community of Argyle is facing a political storm amid serious allegations of conflict of interest, bid-rigging, and a lack of public consultations related to the expansion of aquaculture facilities along the region's coastline. Documents obtained through Freedom of Information requests suggest that municipal staff and local oyster operators worked behind the scenes to fix the locations of Aquaculture Development Areas (ADAs) -placing them adjacent to residential properties without engaging affected residents or conducting meaningful consultation. The controversial site selection has prompted accusations of favouritism and secrecy, with constituents questioning why certain locations were chosen and who benefited. Despite repeated calls for transparency and accountability, the municipality has ignored these concerns. 'People feel betrayed,' said Susan Savriga, an Argyle resident. 'This wasn't a transparent process. It feels like the decisions were made behind closed doors to benefit a few, while the broader community was left in the dark.' Further compounding the issue, The Nova Scotia Department of Fisheries and Aquaculture (DFA) is reported to have approved the contested ADA locations based on the municipality's recommendations-recommendations now mired in claims of improper influence. During a June 2024 council meeting, the Municipality of Argyle confirmed that no meaningful public consultation had been conducted on the site selections-further fuelling community frustration. Top Right to Left: Nolan Deon, and Colton Deon from Deon's Oysters sit behind Deputy Warden Ted Saulnier, Warden Nicole Albright, and CAO Alain Muise during the March 20 session for the municipality of Argyle NS. Evidence and Escalating Concerns Residents allege that municipal councillors and staff enabled specific oyster farmers to secure preferential treatment under the ADA program. In response, the municipality has hired an independent third-party investigator. Simultaneously, the Nova Scotia Ombudsman has launched a separate investigation into the municipality's failure to conduct proper consultation. Despite these developments, the Municipality and DFA have refused to address or resolve the reported conflicts and continue to resist public calls for a reset of the ADA process to perform fair and open public consultations. Rising Barriers to Transparency In what residents describe as an attempt to stifle public oversight, the municipality has begun imposing excessive fees for FOIPOP requests. Additionally, it is invoking Bill 1, recently passed by the provincial government, to label certain information requests as 'trivial, frivolous, or vexatious,' potentially blocking further disclosures. Community Voices Call for Accountability 'Seeing local councillors refuse to represent and listen to their constituents is extremely alarming,' said Lorelei Murphy, Former Liberal Candidate for MLA Argyle. 'Given the volume of concerns and perceived evidence presented by the residents throughout the area, I think it is council's obligation to hold an open and unbiased review of their decisions to this point and act accordingly moving forward.' 'It's clear now that the farmers cheated,' said Chris Thibedeau, a member of the Argyle Residents Association (ARA). 'The email evidence shows individuals inside the municipality helped them. These are no longer perceived conflicts-they are real, and they must be investigated.' 'I've been respectful in all of my communications,' said ARA member Corey Clamp. 'Yet weeks go by with no reply from my councillor. People are watching. If you can't respond to your constituents, you should step down.' As public pressure builds, residents are calling for a full halt to aquaculture approvals until an independent review is completed. The integrity of the municipal governance, they say is on the line. About the ARA The Association for Responsible Aquaculture (ARA) in Argyle is a community stakeholder group of over 400 residents concerned with the lack of transparency and fairness offered by the Aquaculture Development Area (ADA) Pilot led by the Municipality of Argyle and the NS Dept. of Fisheries and Aquaculture. While the ADA is a government led effort, the ARA represents the public and residents of Lobster Bay who seek fairness and a balance of realizing aquaculture expansion in non residential areas in a manner that promotes Tourism and the local harvesting of seafood. ARA is not anti-aquaculture. The goal is to make sure the ADA achieves balance and offers a win for all stakeholders including industry and the public. A photo accompanying this announcement is available at: Videos accompanying this announcement are available at:
Yahoo
14-05-2025
- Politics
- Yahoo
The Association for Responsible Aquaculture Reports Allegations of Bid-Rigging in Nova Scotia Aquaculture Expansion
Argyle Municipality Faces Public Backlash over Conflicts of Interest and Lack of Transparency ARGYLE, Nova Scotia, May 13, 2025 (GLOBE NEWSWIRE) -- The Association for Responsible Aquaculture (ARA) reports that the coastal community of Argyle is facing a political storm amid serious allegations of conflict of interest, bid-rigging, and a lack of public consultations related to the expansion of aquaculture facilities along the region's coastline. Documents obtained through Freedom of Information requests suggest that municipal staff and local oyster operators worked behind the scenes to fix the locations of Aquaculture Development Areas (ADAs) -placing them adjacent to residential properties without engaging affected residents or conducting meaningful consultation. The controversial site selection has prompted accusations of favouritism and secrecy, with constituents questioning why certain locations were chosen and who benefited. Despite repeated calls for transparency and accountability, the municipality has ignored these concerns. 'People feel betrayed,' said Susan Savriga, an Argyle resident. 'This wasn't a transparent process. It feels like the decisions were made behind closed doors to benefit a few, while the broader community was left in the dark.' Further compounding the issue, The Nova Scotia Department of Fisheries and Aquaculture (DFA) is reported to have approved the contested ADA locations based on the municipality's recommendations-recommendations now mired in claims of improper influence. During a June 2024 council meeting, the Municipality of Argyle confirmed that no meaningful public consultation had been conducted on the site selections-further fuelling community frustration. Top Right to Left: Nolan Deon, and Colton Deon from Deon's Oysters sit behind Deputy Warden Ted Saulnier, Warden Nicole Albright, and CAO Alain Muise during the March 20 session for the municipality of Argyle NS. Evidence and Escalating Concerns Freedom of Information (FOIPOP) documents made public via the Argyle Municipality website provide evidence of collusion between select oyster farmers and municipal staff to secure ADA sites and discourage public consultation. (available at this link). Six resident presentations outline detailed conflict of interest claims and are available for public viewing link. At least ten formal complaints from local residents have been filed under Section 12 of the Municipal Conflict of Interest Act, demanding a full investigation. Residents allege that municipal councillors and staff enabled specific oyster farmers to secure preferential treatment under the ADA program. In response, the municipality has hired an independent third-party investigator. Simultaneously, the Nova Scotia Ombudsman has launched a separate investigation into the municipality's failure to conduct proper consultation. Despite these developments, the Municipality and DFA have refused to address or resolve the reported conflicts and continue to resist public calls for a reset of the ADA process to perform fair and open public consultations. Rising Barriers to Transparency In what residents describe as an attempt to stifle public oversight, the municipality has begun imposing excessive fees for FOIPOP requests. Additionally, it is invoking Bill 1, recently passed by the provincial government, to label certain information requests as 'trivial, frivolous, or vexatious,' potentially blocking further disclosures. Community Voices Call for Accountability "Seeing local councillors refuse to represent and listen to their constituents is extremely alarming,' said Lorelei Murphy, Former Liberal Candidate for MLA Argyle. 'Given the volume of concerns and perceived evidence presented by the residents throughout the area, I think it is council's obligation to hold an open and unbiased review of their decisions to this point and act accordingly moving forward." 'It's clear now that the farmers cheated,' said Chris Thibedeau, a member of the Argyle Residents Association (ARA). 'The email evidence shows individuals inside the municipality helped them. These are no longer perceived conflicts-they are real, and they must be investigated.' 'I've been respectful in all of my communications,' said ARA member Corey Clamp. 'Yet weeks go by with no reply from my councillor. People are watching. If you can't respond to your constituents, you should step down.' As public pressure builds, residents are calling for a full halt to aquaculture approvals until an independent review is completed. The integrity of the municipal governance, they say is on the line. About the ARA The Association for Responsible Aquaculture (ARA) in Argyle is a community stakeholder group of over 400 residents concerned with the lack of transparency and fairness offered by the Aquaculture Development Area (ADA) Pilot led by the Municipality of Argyle and the NS Dept. of Fisheries and Aquaculture. While the ADA is a government led effort, the ARA represents the public and residents of Lobster Bay who seek fairness and a balance of realizing aquaculture expansion in non residential areas in a manner that promotes Tourism and the local harvesting of seafood. ARA is not anti-aquaculture. The goal is to make sure the ADA achieves balance and offers a win for all stakeholders including industry and the public. A photo accompanying this announcement is available at: Videos accompanying this announcement are available at: CONTACT: Media Contact: WhatsApp +1-613-884-8162, direct +1-345-938-8162Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
08-05-2025
- Health
- Time of India
Big development in medical science: This cheap and the most popular diabetes drug used worldwide could help fight colon cancer
A popular, inexpensive diabetes medication might have a strong new use. Scientists are now investigating a 20-cent wonder drug, metformin 's potential to aid in the combat against colon cancer, and the early findings are encouraging. #Operation Sindoor Live Updates| From Sindoor to showdown? Track Indo-Pak conflict as it unfolds India hits Lahore's Air Defence Radars in proportionate response Pakistan tried to hit military targets in these 15 Indian cities, New Delhi thwarts strikes This surprising turn of events may be a turning point, particularly since the drug is already widely used and fairly affordable. Experts are cautiously optimistic as the research continues. Although not a cure on its own, initial research indicates that it can enhance other treatments, especially for hard-to-treat cancers. The drug's safety profile and low cost make it a good choice. Continue to video 5 5 Next Stay Playback speed 1x Normal Back 0.25x 0.5x 1x Normal 1.5x 2x 5 5 / Skip Ads by Researchers who gave presentations at last week's American Association for Cancer Research conference in Chicago are examining the interactions between metformin, the most widely used diabetes drug globally, and difficult-to-treat colon cancer cells. They are still in the early stages of their research, as per a report by Business Insider. Holli Loomans-Kropp, a gastrointestinal cancer prevention researcher at The Ohio State University who is spearheading the ongoing study, claimed that metformin "seems like it could have a really interesting supplemental approach to therapy." "We're opening up some doors to what this could do, as quoted in a report by Business Insider. Live Events How does metformin affect colon cancer cells? According to earlier studies, colon cancer rates are lower among diabetics taking metformin, which may indicate that the medication is taking some preventative action against the development of cancer. One of the first studies to examine whether metformin may actually combat colon cancer cells after the disease has progressed is this new one. According to what Loomans-Kropp and her colleagues have observed thus far in cell-culture dishes, metformin may eventually prove to be a useful "supplement" to specific cancer treatment plans. It could be used in conjunction with other treatments, but it wouldn't be strong enough to treat cancer on its own. The drug's potential to treat a common type of colon cancer that is often difficult to treat due to a mutated KRAS gene excites Loomans-Kropp. Before human clinical trials can start, more animal testing is necessary, so her research is still in its early phases. Why are researchers optimistic about metformin's potential? The fact that metformin is a medication that is already widely available and reasonably priced makes it a practical choice for treating colon cancer, according to Loomans-Kropp. Millions of people around the world have studied and taken metformin, which is inexpensive as an off-patent generic medication that costs 10 to 20 cents per pill. Because it controls how the body uses energy and promotes autophagy, which enables the body to break down old and damaged cells, some scientists think it may have potential as an antiaging medication. According to Loomans-Kropp, metformin may also prevent colon cancer cells from utilising energy for growth and development. What's next in the study before human trials begin? Metformin as a disease prevention tool excites longitudinal researchers. Metformin may be a "suitable" option for cancer prevention, according to Dr. Nir Barzilai, a renowned longevity researcher who believes the medication may be helpful for healthy ageing. Within a year, she can start testing metformin as a treatment for colon cancer in animals if these preliminary cancer cell results are positive. FAQs Does metformin cure colon cancer? No, but it may supplement other treatments, particularly for aggressive forms of the disease. Why is metformin being considered as a cancer treatment? As it alters how cells use energy, it may slow cancer growth; additionally, it is inexpensive and already widely used.
